Our valued sponsor

Drugmaker Chooses Lone Wolf Strategy

guest

Cyprus Company Formation
Advance Member
Dec 30, 2008
13,877
41
48
75
Visit site
On October 6, shares of pharmaceutical startup MannKind Corp. plummeted 30% to $6.30, when the company predicted it wouldn't sign a partnership deal with a well-capitalized Big Pharma company until after its experimental drug is approved. Here's the twist: MannKind's experimental drug is inhaled ...


More...